Panacea Biotec Reports Significant Decline in Profitability Metrics for March 2025

Panacea Biotec, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a challenging period for the company, with notable shifts in its financial metrics.
The Profit Before Tax less Other Income (PBT) for the quarter stands at Rs -36.34 crore, reflecting a significant decline compared to the previous year. Similarly, the Profit After Tax (PAT) has also shown a marked downturn, recorded at Rs -29.60 crore. This represents a substantial change in the company's profitability landscape.

Additionally, the Operating Profit (PBDIT) has reached its lowest point in the last five quarters at Rs -26.88 crore, indicating a concerning trend in operational efficiency. The Operating Profit Margin has also declined to -20.28%, further highlighting the challenges faced by the company in maintaining profitability.

In light of these developments, Panacea Biotec has experienced an adjustment in its evaluation, with its score reflecting these recent financial challenges.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.